The Pharmaletter
NodThera
A leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome.
Company Overview
Latest NodThera News
21 July 2025
12 October 2020
3 June 2020
20 September 2019
Today's issue
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze